UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

British journal of cancer, 2009-01, Vol.100 (2), p.266-273

2009

Volltextzugriff (PDF)

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Annals of oncology, 2008-04, Vol.19 (4), p.734-738

2008

Volltextzugriff (PDF)

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

British journal of cancer, 2009-07, Vol.101 (2), p.357-362

2009

Volltextzugriff (PDF)

Do medical students copy the drug treatment choices of their teachers or do they think for themselves

European journal of clinical pharmacology, 2010-04, Vol.66 (4), p.407-412

2010

Volltextzugriff (PDF)

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

Investigational new drugs, 2008-08, Vol.26 (4), p.393-397

2008

Volltextzugriff (PDF)

Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study

Annals of oncology, 2006-10, Vol.17 (10), p.1523-1528

2006

Volltextzugriff (PDF)

UGT1A128 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

British journal of cancer, 2008-07, Vol.99 (2), p.275-282

2008

Volltextzugriff (PDF)

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

British journal of cancer, 2008-10, Vol.99 (8), p.1316-1321

2008

Volltextzugriff (PDF)

Glutathione- S -transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

European journal of cancer (1990), 2009-03, Vol.45 (4), p.572-578

2009

Volltextzugriff (PDF)

The correlation between ERCC1 expression and outcome of chemotherapy in patients with advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group study (DCCG)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.11042-11042

2008

Volltextzugriff (PDF)

Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.2574-2574

2008

Volltextzugriff (PDF)

UGTIAI28 genotype and irinotecan dosage in patients with metastatic colorectal cancer : a Dutch Colorectal Cancer Group study

British journal of cancer, 2008, Vol.99 (2), p.275-282

2008

Volltextzugriff (PDF)

GSTPI lle 105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

British journal of cancer, 2008-10, Vol.99 (8), p.1316-1321

2008

Volltextzugriff (PDF)

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.LBA4011-LBA4011

2008

Volltextzugriff (PDF)

GSTP I Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan : a study of the Dutch Colorectal Cancer Group

British journal of cancer, 2008, Vol.99 (8), p.1316-1321

2008

Volltextzugriff (PDF)

Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4012-4012

2007

Volltextzugriff (PDF)

Use of microsatellite instability in non-hereditary advanced colorectal cancer to predict response to chemotherapy and overall survival: A study of the Dutch Colorectal Cancer Group (DCCG)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4118-4118

2007

Volltextzugriff (PDF)

DNA methylation is a comprehensive marker for pediatric adrenocortical tumors

Endocrine-related cancer, 2022-11, Vol.29 (11), p.599-613

2022

Volltextzugriff (PDF)

IMPLICATIONS OF THE DELAYED 2013 OUTBURST OF ESO 243-49 HLX-1

The Astrophysical journal, 2014-10, Vol.793 (2), p.1-13

2014

Volltextzugriff (PDF)

A novel gain‐of‐function mutation in ORAI1 causes late‐onset tubular aggregate myopathy and congenital miosis

Clinical genetics, 2017-05, Vol.91 (5), p.780-786

2017

Volltextzugriff (PDF)

MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis

American journal of neuroradiology : AJNR, 2021-11, Vol.42 (11), p.2077-2085

2021

Volltextzugriff (PDF)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

Annals of surgical oncology, 2010-09, Vol.17 (9), p.2411-2418

2010

Volltextzugriff (PDF)

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Lancet neurology, 2021-07, Vol.20 (7), p.526-536

2021

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(234)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

Do medical students copy the drug treatment choices of their teachers or do they think for themselves

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study

UGT1A128 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

Glutathione- S -transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

The correlation between ERCC1 expression and outcome of chemotherapy in patients with advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group study (DCCG)

Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial

UGTIAI28 genotype and irinotecan dosage in patients with metastatic colorectal cancer : a Dutch Colorectal Cancer Group study

GSTPI lle 105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

GSTP I Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan : a study of the Dutch Colorectal Cancer Group

Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study

Use of microsatellite instability in non-hereditary advanced colorectal cancer to predict response to chemotherapy and overall survival: A study of the Dutch Colorectal Cancer Group (DCCG)

DNA methylation is a comprehensive marker for pediatric adrenocortical tumors

IMPLICATIONS OF THE DELAYED 2013 OUTBURST OF ESO 243-49 HLX-1

A novel gain‐of‐function mutation in ORAI1 causes late‐onset tubular aggregate myopathy and congenital miosis

MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis

Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Suchergebnisse filtern